HIV-1 neutralizing activity is correlated with increased levels of chemokines in saliva of HIV-1-exposed uninfected individuals

Curr HIV Res. 2008 Jan;6(1):28-33. doi: 10.2174/157016208783571964.

Abstract

Aim: Mucosal HIV-1 exposure stimulates a variety of mucosal immune responses, including IgA1-mediated virus neutralization, even in the absence of an established infection. We hypothesized that other immune molecules might also contribute to the HIV-1 neutralizing activity observed in the mucosal secretions of HIV-1 exposed uninfected individuals.

Methods: Saliva samples were collected from HIV-1 seronegative high-risk female sex workers (FSW) from Nairobi. Samples were also collected from HIV-1 IgG positive FSW and HIV-1 IgG negative low-risk women from the same geographical area. In all samples, IgA2, secretory leukocyte protease inhibitor (SLPI), regulated on activation, normal T-cell expressed and secreted (RANTES), macrophage inflammatory protein 1 alpha and beta (MIP-1alpha and -beta) and monocyte chemoattractant protein-1 (MCP-1) were quantified. The IgA1-depleted saliva samples were subsequently tested for neutralizing capacity in a PBMC-based neutralization assay using a primary HIV-1 clade A isolate to determine biological relevance of the measured molecules.

Results: HIV-1 specific neutralization was present in the IgA1-depleted fraction from saliva of both HIV-1 seropositive (9 of 10) and high-risk individuals (36 of 45) but not in HIV-1 IgG-negative control subjects (0 of 8). In the high-risk individuals, higher levels of CC-chemokines were seen in those that could neutralize HIV-1 as compared with those that could not (P<0.05).

Conclusion: The HIV-1 neutralizing activity in saliva of HIV-1-exposed high-risk individuals is not only mediated by IgA1, but is also present in IgA1-depleted fractions and is associated with increased levels of CC-chemokines. Such innate immune factors may be important in limiting HIV-1 mucosal transmission.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Chemokine CCL2 / immunology*
  • Chemokine CCL3 / immunology*
  • Cohort Studies
  • Cross-Sectional Studies
  • Female
  • HIV Infections / immunology*
  • HIV-1 / immunology*
  • Humans
  • Immunity, Innate / immunology*
  • Immunoglobulin A / analysis
  • Immunoglobulin A / immunology
  • Neutralization Tests
  • Saliva / chemistry
  • Saliva / immunology*
  • Secretory Leukocyte Peptidase Inhibitor / immunology
  • Sex Work

Substances

  • CCL2 protein, human
  • CCL3 protein, human
  • Chemokine CCL2
  • Chemokine CCL3
  • Immunoglobulin A
  • SLPI protein, human
  • Secretory Leukocyte Peptidase Inhibitor